Abcellera Biologics(ABCL.US)

Last Updated 19:00:00 ET
longbridge loading

Is AbCellera (ABCL) Quietly Rewriting Its Business Model With ABCL635’s Phase II Menopause Bet?

Simplywall·
US
ABCL
-2.64%
US
FBT
+0.54%
US
XBI
-0.69%
Simplywall·
US
ABCL
-2.64%
US
FBT
+0.54%
US
XBI
-0.69%

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga_article·
US
PACS
-0.24%
US
WOK
-38.16%
US
ABCL
-2.64%
benzinga_article·
US
PACS
-0.24%
US
WOK
-38.16%
US
ABCL
-2.64%

AbCellera Biologics shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article·
US
ABCL
-2.64%
US
LABU
-2.35%
US
IBB
+0.10%
benzinga_article·
US
ABCL
-2.64%
US
LABU
-2.35%
US
IBB
+0.10%

Abcellera Biologics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.315 M

Earnings Watch·
US
ABCL
-2.64%
Earnings Watch·
US
ABCL
-2.64%

Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara

Pharmaceutical Technology·
US
ABCL
-2.64%
US
IHE
+1.26%
US
XBI
-0.69%
Pharmaceutical Technology·
US
ABCL
-2.64%
US
IHE
+1.26%
US
XBI
-0.69%

AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot Flashes

Market Beat·
US
ABCL
-2.64%
US
XBI
-0.69%
US
LABU
-2.35%
Market Beat·
US
ABCL
-2.64%
US
XBI
-0.69%
US
LABU
-2.35%

AbCellera Biologics (ABCL) Is Up 6.8% After Announcing First Human Data Timeline For ABCL635

Simplywall·
US
ABCL
-2.64%
US
BIB
+0.05%
US
SBIO
-1.24%
Simplywall·
US
ABCL
-2.64%
US
BIB
+0.05%
US
SBIO
-1.24%

Top European Undervalued Small Caps With Insider Action In April 2026

Simplywall·
US
ABCL
-2.64%
US
BBH
+0.68%
US
FBT
+0.54%
Simplywall·
US
ABCL
-2.64%
US
BBH
+0.68%
US
FBT
+0.54%
© 2026 Longbridge｜Disclaimer